Evolution of Vg9Vd2 T cells

被引：0
|
作者：
Karunakaran, M. M. [1 ]
Starick, L. [1 ]
Goebel, T. W. [2 ]
Herrmann, T. [1 ]
机构：
[1] Univ Wurzburg, Inst Virol & Immunobiol, D-8700 Wurzburg, Germany
[2] Univ Munich, Dept Vet Sci, Inst Anim Physiol, Munich, Germany
来源：
IMMUNOLOGY | 2012年 / 137卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：399 / 399
页数：1
相关论文
共 50 条
  • [1] Generation and application of TGFb-educated human Vg9Vd2 T cells
    Parente-Pereira, Ana C.
    Beatson, Richard E.
    Davies, David M.
    Hull, Caroline
    Whilding, Lynsey M.
    Porter, Joanna C.
    Maher, John
    STAR PROTOCOLS, 2022, 3 (02):
  • [2] Immunotherapy of acute myeloid leukemia using Vg9Vd2 T-cells
    Parente-Pereira, Ana C.
    Whilding, Lynsey M.
    Krishnamurthy, Pramila
    Beatson, Richard
    Zabinski, Tomasz
    Barber, Linda
    Farzaneh, Farzin
    Mufti, Ghulam
    Maher, John
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [3] Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells
    Paniagua-Herranz, Lucia
    Diaz-Tejeiro, Cristina
    Sanvicente, Adrian
    Bartolome, Jorge
    Nieto-Jimenez, Cristina
    Ocana, Alberto
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [4] IL-18 Reconstitutes Vg9Vd2 T Cells in HIV plus Patient Samples
    Murday, Alanna
    Pauza, C. David
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 : 93 - 93
  • [5] TARGETING BTN2A1 MODULATES ANTI-TUMOR ACTIVITY OF VG9VD2 T CELLS
    Cano, Carla
    de Gassart, Aude
    Pasero, Christine
    Gabriac, Melanie
    Fullana, Marie
    Granarolo, Emilie
    Hoet Rene
    Imbert, Caroline
    Gorvel, Laurent
    Briantais, Antoine
    Le Floch, Anne-Charlotte
    Olive, Daniel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A126 - A127
  • [6] BTN2A, a New Immune-Checkpoint Targeting Vg9Vd2 T Cell Cytotoxicity
    Cano, Carla E.
    Pasero, Christine
    De Gassart, Aude
    Hoet, Rene
    Scotet, Emmanuel
    Mortier, Erwan
    Quemeneur, Agnes
    Rafia, Chirine
    Briantais, Antoine
    Le Floch, Anne-Charlotte
    Olive, Daniel
    BLOOD, 2019, 134
  • [7] TCR and DNAM Dependent Lysis of Acute Monocytic Leukemia (AMoL) by Vg9Vd2 T Lymphocytes.
    Gertner-Dardenne, Julie
    Perrot, Eloise
    Prebet, Thomas
    Charbonnier, Aude
    Sicard, Helene
    Vey, Norbert
    Olive, Daniel
    BLOOD, 2009, 114 (22) : 431 - 431
  • [8] BSI-093, a best-in-class anti-BTN3A monoclonal antibody for cancer immunotherapy by activation of Vg9Vd2 T cells
    Dai, Wenwen
    Li, Jun
    Liu, Jinyu
    Li, Hongyan
    Liu, Xiaodong F.
    Xia, Shukai
    Lyu, Qun
    Davis, Hugh M.
    Chen, Mingjiu
    Peng, Zeyu
    CANCER RESEARCH, 2024, 84 (06)
  • [9] ICT01, AN ANTI-BTN3A MAB THAT ACTIVATES VG9VD2 T CELLS, PLUS INTERLEUKIN-2: A POTENT AND PROMISING COMBINATION FOR CANCER IMMUNOTHERAPY
    de Gassart, Aude
    Brune, Patrick
    Suong, L. E.
    Agaugue, Sophie
    Valentin, Emmanuel
    Sims, Jennifer
    Olive, Daniel
    Frohna, Paul
    Hoet, Rene
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A268 - A269
  • [10] Bromohydrin pyrophosphate (IPH1101 or phosphostim™) a VG9VD2 T lymphocytes agonist.: Phase 1 clinical study results
    Bennouna, Jaafar
    Levy, Vincent
    Sicard, Helene
    Rolland, Frederic
    Misset, Jean L.
    Beautier, Lucile
    Bompas, Emmanuelle
    de Micheaux, Sylvie Lafaye
    Tiollier, Jerome
    Calvo, Fabien
    ANNALS OF ONCOLOGY, 2006, 17 : 141 - 141
12345